BrainPatch is proud to be part of REVERSE, an international research and development project with a total consortium budget of over €2.6 million. Supported through the Eurostars programme, the three-year collaboration brings together technology developers and clinical researchers from the Netherlands, the United Kingdom, and Switzerland to work towards a shared goal: predicting epileptic seizures and intervening before they develop.
The consortium combines the expertise of three complementary partners:
Alpha Brain Technologies, Netherlands, leads system integration and AI-based seizure prediction, developing the intelligence that will analyse brain activity and identify signs of an approaching seizure.
BrainPatch, United Kingdom, contributes its expertise in non-invasive neurostimulation and device manufacturing, developing the stimulation technology within the integrated system.
Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland, leads clinical validation, bringing specialist expertise in epilepsy to the evaluation of the technology.
REVERSE focuses on drug-resistant epilepsy, where seizures remain uncontrolled despite medication. The project aims to develop a wearable system that continuously monitors brain activity through an EEG patch. AI algorithms would analyse the signals in real time and, when a high-risk state is identified, automatically trigger non-invasive neurostimulation. The goal is to prevent seizures or reduce their severity.
This “closed-loop” approach connects monitoring, prediction, and stimulation in one system. By combining these capabilities, the consortium hopes to help people living with unpredictable seizures gain greater independence and improve their quality of life.
Running from April 2026 to April 2029, the project will develop and clinically evaluate a prototype, laying the groundwork for subsequent larger-scale trials. Establishing its safety and effectiveness is a central part of that work.
BrainPatch’s participation is supported by a £310,338 grant from Innovate UK, part of UK Research and Innovation, towards its £517,230 project costs.
We thank our consortium partners and Innovate UK for supporting this collaboration. We look forward to sharing our progress as we work together towards new possibilities in epilepsy care.